ASKG315 not checked

AskGene Pharma, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.”In the company’s words, NCT05509985 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors (2 trials)
Main trialPhase 1
“The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced solid tumors.”In the company’s words, NCT05509985 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors

All 2440 drugs for Advanced Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Unknown 9 Sep 2023 A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
Phase 1Unknown 31 Dec 2023 A Study of ASKG315 in Patients With Advanced Solid Tumors.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ASKG315

Following is part of Solo: you see every change to ASKG315 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in